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Abstract 11 
The synthesis and biological activity of a variety of analogues to the naturally occurring anti-12 
bacterial and anti-fungal Distamycin A were explored by a number of authors.  These 13 
compounds were subject to a large array of assays. Some of these compounds showed high 14 
activity against a range of Gram-positive, Gram-negative bacteria as well as fungi. To 15 
explore the anti-parasitic activity of this class of compounds, specific modifications had to be 16 
made. A number of these compounds proved to be active against Trypanosoma brucei. The 17 
binding of a number of these compounds to short sequences of DNA were also examined 18 
using footprinting assays as well as NMR spectroscopy. Computer modelling was employed 19 
on selected compounds to understand the way these compounds bind to specific DNA 20 
sequences. A large number of variations were made to the standard structure of Distamycin. 21 
These changes involved the replacement of the pyrrole moieties as well as the head and tail 22 
groups with a number of heterocyclic compounds. Some of these MGBs were also 23 
investigated for their capability for the treatment of cancer and in particular lung cancer. 24 
Keywords: Minor Groove Binders, Distamycin, Netropsin, Antibacterial, Thiazotropsin A, 25 
Clostridium difficile 26 
1. Introduction 27 
Minor Groove Binders (MGBs) is a large family of compounds called Lexitropsins which 28 
bind to the minor groove of the DNA (Deoxyribonucleic acid) and are thus DNA binding 29 
ligands.1-22 This binding can vary from one molecule to another depending on the variations 30 
made on the MGBs. The first two compounds discovered were Distamycin A and Netropsin. 31 
Distamycin A is a naturally occurring antibiotic which was isolated in 1962 from the cultures 32 
of Streptomyces distallicus. These were found to be active against a variety of viruses, Gram-33 
positive bacteria and protozoa. However, some of these were inactive as antitumor agents. 34
The structure of distamycin, (Scheme 1), shows the presence of an oligopeptidic 35 
pyrrolecarbamoyl structure ending with an amidino moiety. Distamycin A reversibly binds to 36 
the minor groove of DNA by hydrogen bonds, van der Waals contacts and electrostatic 37 
interactions. These have a strong preference for adenine-thymine (AT) rich sequences 38 
containing at least four AT base pairs.23 39 
If the number of pyrrole rings in an MGB increases to four, the activity will increase to 40 
around 20-fold compared to distamycin A. This will also lead to an increase in the sequence 41 
specificity for longer tracts of AT-rich DNA and this is as a consequence of the greater 42 
availability of hydrogen bonding and van der Waals surface interactions.  43 
Aleksic et al59 explored the field of minor groove binders by incorporating organic 44 
compounds such as (mitomycin C and anthramycin) and inorganic compounds such as 45 
cisplatin in their studies. While Vafazadeh et al60 reported the interaction of copper (II) 46 
complexes with DNA. Alcohol containing netropsin type symmetrical compounds were 47 
successfully prepared by Khan et al61. They also managed to construct various unsymmetrical 48 
triaryl compounds and further explored the activity of these compounds. Others62 have 49 
studied a number of small indole derivatives for their DNA binding ability using fluorescence 50 
quenching experiments as well as molecular docking technique. 51 
Discussion 52 
 53 
54 
 55 
Scheme 1: The structure of DNA minor groove binders: Distamycin A and Netropsin 56 
 57 
1.1. The naturally occurring compounds Distamycin and Netropsin (Scheme 1) are the 58 
most studied compounds in this field. In our earlier studies we modified the MGBs by 59 
introducing various alkyl groups on the pyrrole nitrogen as well as C-alkyl substitution and 60 
this meant leaving the head group as in the naturally occurring compound. However, the tail 61 
group was replaced with dimethylaminopropyl (DMAP).50 These compounds (Scheme 2) 62 
show a number of examples of the MGBs which bind to the minor groove in a ratio of either 63 
2:1 or 1:1 depending on the alkyl bulky group. However, when there were several alkyl 64 
groups attached to the heterocyclic ring (pyrrole), this led to a weak binding or no binding at 65 
all to the sequence AAATTATATTAT in the electrophoresis (CE) experiments.9 66 
 67 
3 R1 = R2 = R3 = Me; R4 = H 2 to 1 
4 R1 = R3 = Me; R2 = Et; R4 = H 2 to 1 
5 R1 = R3 = Me; R2 = isppropyl; R4 = H 2 to 1 
6 R1 = R3 = Me; R2 = Cyclopentyl; R4 = H 2 to 1 
7 R1 = R3 = Me; R2 = Cyclopropyl; R4 = H 2 to 1 
8 R1 = R3 = isopropyl; R2 = Me; R4 = H 1 to 1 
9 R1 = R3 = Me; R2 = isopentyl; R4 =H 2 to 1 
10 R1 = R2 = R3 = isopropyl; R4 = H Weak Binding 
11 R1 = R2 = R3 = isopentyl; R4 = H No Binding 
12 R1 = R2 = R3 = R4 = Me No Binding 
Scheme 2: Compounds synthesised and studied together with their binding to the 68 
sequence AAATTATATTAT as measured by CE (Reference 9 with permission from: J. 69 
Med. Chem.) 70 
 71 
Khalaf et al,9 reported a large number of DNA minor groove binders bearing a variety of 72 
alkyl groups on the heterocyclic rings. Also, the pyrrole ring was replaced with a range of 73 
heterocyclic rings: such as thiazole, thiophene, imidazole and oxazole. 74 
They also reported the biological activity (Table 1) of these compounds against a number of 75 
Gram negative, Gram positive bacteria as well as fungi. Here is a small selection as a 76 
representative example of these MGBs. 77 
 78 
Table 1: 79 
Antibacterial and antifungal activity of selected compounds: 80 
Antibacterial activity (MIC, M x 106) Antifungal activity (MIC, M x 106) 
compound S.aur S.fae MRSA E.clo M.for K.aer P.vul E.col A.nig A.nid C.alb 
3 10.0 0.31 na na na 164 na na na na na 
5 na 157 157 na na 39.1 157 na 157 na Na 
6 75.0 75.0 75.3 na 75.3 na na na 37.6 nt 75.3 
7 153.0 76.9 76.9 76.9 38.4 38.4 na na na 153 76.9 
8 na na 150 na na na na na na 150 75 
9 150 57.5 150 150 37.5 37.5 150 na 150 na 150 
10 144 72 144 36 72 36 144 na 72 72 144 
12 na na na na 153 77.7 153 na 153 153 na 
amoxicillin 0.49 0.49 16.1 4 16.1 8.1 4 - - - - 
Streptomycin 10.8 - - - - - - - - - - 
Fluconazole - - - - - - -  >300 90.8 81.6 
Itraconazole - - - - - - - - 17.7 35.4 35.4 
Abbreviations for microbes: S.aur = S.aureus NCTC 6571. S.fae = S.faecalis NCTC 775. 81 
MRSA = MRSA PHLS M1. E.clo = E.coli NCTC 9001. A.nig = A.niger IM117454. 82 
A.nid = A.nidulans CABI 0160037. C.alb = C.albicans NCPF 3179 83 
(Reference 9 with permission from: J. Med. Chem.) 84 
 85 
1.2. MGBs containing one or more heterocyclic rings other than pyrrole 86 
1.2.1. MGBs containing isopropylthiazole 87 
Several heterocyclic rings were incorporated in the synthesis of the MGBs and among these 88 
were isopropyl-thiazole. Khalaf et al,5,23 published several research papers in this field since 89 
it exhibits unique binding to the minor groove. These compounds showed very specific 90 
binding to a region of DNA which was identified by footprinting, NMR studies and CE 91 
measurements.9 This binding domain is ACTAGT and this molecule binds in a ratio of 2:1 92 
and head to tail fashion (Scheme 3). 93 
Antony et al,8,9 have studied this molecule extensively due to its selectivity to the GC region 94 
of the oligonucleotides. This molecule was later named E\WKHDXWKRUVDV³7KLD]RWURSVLQ$´95 
NMR as well as molecular modelling studies produced a vast amount of information about 96 
the behaviour of this molecule. Figs. 1-3 as well as Scheme 3 illustrate the way this molecule 97 
winds itself around the oligonucleotide [DNA duplex d(CGACTAGTCG)2] in a head to tail 98 
fashion. Two molecules of this compound bind side-by-side in the minor groove however, 99 
because of the bulky ³LVRSURS\O´RIWKHVXEVWLWXWHGWKLD]ROHULQJWKHtwo molecules are 100 
staggered relative to each other and the complex reads a total of 6 base pairs. 101 
 102 
Scheme 36WUXFWXUHRI³7KLD]RWURSVLQ$´ 103 
  104 
(A)                                                                    (B) 105 
 106 
Fig. 1: Representation of the solution structure of the complex between two thiazotropsin A 107 
molecules (1 and 2) determined in aqueous solution by NMR spectroscopy. (A) Overlay of a 108 
family of 10 lowest energy structures taken from different parts of the molecular dynamics 109 
trajectory; the ligand is represented in gold. (B) CPK representation of the average structure 110 
looking into the minor groove: ligand, atoms coloured by atom type; DNA, all atoms shown 111 
in blue. 112 
(Reference 11 with permission from: J. Amer. Chem. Soc) 113 
  114 
 115 
Fig. 2: Cartoon and schematic representation of the complex between two thiazotropsin A 116 
molecules (1 and 2) showing the location of 1 with respect to the DNA sequence. See 117 
reference [11] for additional information. 118 
(Reference 11 with permission from: J. Amer. Chem. Soc) 119 
  120 
 121 
 122 
Fig. 3: Expected arrangement of hydrogen bonding between 1 and the DNA duplex 123 
d(CGACTAGTCG)2, 2. 124 
(Reference 11 with permission from: J. Amer. Chem. Soc) 125 
  126 
Figs. 1-3 showed that the researchers have managed to design molecules which can recognise 127 
each other and bind to a specific oligonucleotide in a side-by-side and head to tail fashion. 128 
Branched alkyl groups were introduced into the design of the minor groove binding 129 
molecules at the University of Strathclyde. Distamycin A analogues having an isopropyl 130 
moiety joint to the pyrrole ring have attracted the interest of many researchers.12 These 131 
compounds have shown higher affinity than the original Distamycin A and it showed a 132 
different pattern of binding selectivity.9 The use of thiazole instead of pyrrole is very 133 
interesting since the sulfur atom is large and should have a major effect on partitioning into 134 
biological membranes. Thiazotropsin A has both the branched alkyl side chain (isopropyl) 135 
and the thiazole moiety. This will make the adjacent part of the molecule very bulky and 136 
hydrophobic. DNA footprinting studies with thiazotropsin A using a 200 base pair DNA 137 
construct revealed only one binding site FHQWHUHGDURXQGWKHVHTXHQFH¶-ACTAGT-¶9 138 
which had a very high affinity. 139 
 140 
1.2.2. 0*%VFRQWDLQLQJ³LVRSURS\OWKLD]ROH´DQG³N-PHWK\OLPLGD]ROH´ 141 
Parkinson et al,17 have managed to determine the sequence specificity of a closely related 142 
compound to thiazotropsin A, in which one of the N-methylpyrrole group was replaced with 143 
N-methylimidazole; this was named thiazotropsin B (Scheme 4a). By comparison with the 144 
Dervan rules for sequence recognition, and allowing for the staggered side-by-side binding of 145 
these compounds, the authors17 predicted that this compound should bind to the sequence 146 
(A/T)CGCG(A/T). They have used DNase I and hydroxyl radical footprinting and 147 
fluorescence melting to explore the sequence specificity of this compound. Thiazotropsin A 148 
was prepared as previously described,4,7,12,15 while thiazotropsin B was synthesized as 149 
described below (Schemes 4a, 4b). 150 
 151 
 152 
Scheme 4a6\QWKHVLVRI³7KLD]RWURSVLQ%´ 153 
 154 
Fig. 4 shows the results of DNase I and hydroxyl radical footprinting experiments with these 155 
compounds on DNA fragments MS1 and MS2.25,49 These footprinting substrates contain all 156 
the 136 possible tetranucleotide sequences: MS1 and MS2 contain the same sequence, which 157 
was cloned in opposite orientations, allowing good resolution of target sites at both ends of 158 
the fragment. The authors expected that thiazotropsin B would possess a binding site that is 159 
longer than four base pairs (probably (A/T) CGCG(A/T). The first two panels of Fig. 4 show 160 
the DNase I cleavage patterns, in which three footprints are evident on each strand, which are 161 
indicated alongside the sequence in Fig.4. 162 
 163 
 164 
(Fig.4): The first two panels show DNase I footprints for thiazotropsin B on MS1 (top strand, Figure 4A) and 165 
MS2 (bottom strand, Figure 4B). The third panel compares the DNase I footprints for thiazotropsin A (10 µM) 166 
DQGWKLD]RWURSVLQ%0RQ06µ$¶LQGLFDWHVWKHORFDWLRQRIWKHELQGLQJVLWHIRUWKLD]RWURSVLQ$7KH167 
fourth and fifth panels show hydroxyl radical cleavage patterns for these ligands on the MS2 fragment. The final 168 
panel shows DNase I cleavage patterns of Sequence A in the presence of thiazotropsin B. Ligand concentrations 169 
(µM) are shown at the top of each gel lane. GA corresponds to marker lanHVVSHFLILFIRUSXULQHVZKLOHµFRQ¶LV170 
cleavage in the absence of added ligand. The filled boxes show the location of the best binding sites. 171 
(Reference 15 with permission from: Bioorg. & Med. Chem. Letters), license number: 172 
3905281229232 173 
 174 
The concentrations required to generate these footprints (10 µM and above) are higher than 175 
those previously reported for thiazotropsin A (1 µM). The footprint at site 1 persists to lower 176 
concentrations (10 µM) than the other two sites (25 µM). This site contains the sequence 177 
GCGCGA, which differs from the predicted target, (A/T)CGCG(A/T), at only the first base 178 
pair. They have previously shown that thiazotropsin A binds to the sequence ACTAGT and it 179 
is clear that thiazotropsin B binds at a different location. This is emphasized in the third panel 180 
of Fig. 4 which directly compares the DNase I footprinting patterns of these two ligands. The 181 
IRRWSULQWIRUWKLD]RWURSVLQ$ODEHOOHGµ$¶LVQRWDIIHFWHGE\WKLD]RWURSVLQ%DQGWKHWKUHH182 
thiazotropsin B sites are not affected by thiazotropsin A. It is clear that these two ligands 183 
have very different sequence binding requirements, even though they only differ by a single 184 
atom. Site 2 contains the sequence TCCCGT, which also differs from the predicted target at 1 185 
bp in the third position. Site 3, which contains the sequence TAGCAA, is less closely related 186 
and differs from the predicted sequence in the second and fourth positions.12,15 187 
 188 
 189 
Fluorescently labelled sequences used in the thermal melting experiments (Scheme 4b) were: 190 
F = fluorescein and Q = methyl red. 191 
 192 
 193 
Structure of thiazotropsin A (X = C. R = H) and thiazotropsin B (X = N, R = CH3) 194 
Name Sequence  
ACGCGT ¶-F-CCGACGCGTGC-¶ 
¶-Q-GGCTGCGCACG-¶ 
ACTAGT ¶-F-CCGACTAGTGC-¶ 
¶-Q-GGCTGATCACG-¶ 
Scheme 4b: Structure and binding properties of thiazotropsin A and B 195 
(Reference 15 with permission from: Bioorg. & Med. Chem. Letters), license number: 196 
3905281229232 197 
 198 
 199 
2. MGBs with anti-parasitic activity: 200 
Minor Groove Binders have been used against trypanosomiasis since the 1930s. This is 201 
exemplified by the use of bis-amidines, pentamidine and diminazene. These were used as the 202 
first-line treatments for Human African Trypanosomiasis (HAT) and Animal African 203 
Trypanosomiasis (AAT), consecutively.47 A large number of similar compounds have been 204 
synthesised and evaluated against trypanosomiasis and, moreover, many have been found 205 
useful against protozoan infections, including leishmaniasis and malaria.48 206 
Trypanosoma brucei is a species of parasitic protozoan. It causes African trypanosomiasis, 207 
which is also known as sleeping sickness in humans and nagana in animals.35 T. brucei can be 208 
divided into three subspecies: T. b. brucei, T. b. gambiense and T. b. rhodesiense. The latter 209 
two are parasites of humans, while the first is that of animals. Only rarely can the T. b. brucei 210 
infect a human. T. b. brucei is transmitted between mammal hosts by an insect vector which 211 
belongs to the species of tsetse fly. The transmission occurs by biting during the insect's 212 
blood meal. The parasites undergo several morphological changes as they move between 213 
insect and mammal over the course of their life cycle. T. brucei is one of only a few 214 
pathogens that have the capability of crossing the blood brain barrier.36 New drug therapies 215 
are urgently needed to be developed, as existing treatments can prove fatal to the patient.37,38 216 
This parasite was first discovered in 1894 by Sir David Bruce, after whom the scientific name 217 
was given in 1899.39,40 218 
Lang and others have designed MGBs that interfered with the DNA of certain parasites. This 219 
was demonstrated in a number of publications.26,29,30 These were thiazole containing 220 
compounds, activity was found against Trypanosoma brucei, Table 2 and Table 3. 221 
  222 
Table 2:  223 
Selected examples of anti-trypanosomal activity of heterocyclic oligoamide dimers and 224 
trimers (for more examples see reference 26) 225 
Compound Structure Activity 
MIC(µM) 
23 
 
2.20 
24 
 
8.74 
25 
 
0.715 
26 
 
3.12 
 226 
  227 
Table 3:  228 
Selected examples of anti-trypanosomal activity of heterocyclic oligoamide trimers (for more 229 
examples see reference 26) 230 
Compound Structure Activity 
MIC(µM) 
15 
 
1.56 
 
16 
 
0.0634 
17 
 
0.78 
18 
 
1.92 
19 
 
0.815 
20 
 
>25 
 231 
  232 
Of particular interest is a molecule which does not contain a typical basic flexible tail group 233 
found in MGBs, but instead has an unprotected carboxylic acid group at that position 234 
(compound 16 which has activity of 63 nM against T. brucei). These compounds showed 235 
consistent activity against T. brucei. 2-Amino-5-alkylthiazole 4-carboxylic acid derivatives 236 
(Scheme 5 and 6) were found to be common components of the active compounds. It was of 237 
interest, therefore, to investigate the structure±activity relationship in this series in particular 238 
by reducing the size of the compounds from the original tetracyclic minor groove binders so 239 
that these compounds would be more drug-like. Trypanosomes have characteristic structures, 240 
known as kinetoplasts, in which circular DNA is packaged densely within a large 241 
mitochondrion.27,28 Assays for activity against T. brucei were carried out using established 242 
methods at the laboratories in Strathclyde and Glasgow Universities.29 Compound 20 is 243 
typical of an anti-bacterial and anti-fungal minor groove binder with an MIC vs. S. Aureus 244 
4.3 µM, vs. A. niger 4.3 µM. However, this compound was found to be inactive against T. 245 
brucei. The C-terminal compound 16 showed the highest activity of 63 nM. This was the 246 
highest activity found in any of the compounds investigated by the authors.24 The 247 
corresponding ester 15 and the piperazinyl amide 18 were 20±30-fold weaker in activity; and 248 
the morpholine amides 17 and 19 were 3-10 fold weaker in activity, although they have the 249 
same basic structures. Tables 2 and 3 showed the results for the dimers and these appeared to 250 
have weaker activity than the trimers. The greatest activity was found in compounds 251 
containing the dimethylaminopropyl C-terminal amide (Scheme 5 and 6).27 The 252 
dimethylaminopropyl group is common in antibacterial minor groove binders.9,16,30 The 253 
ionized C-terminal group which is protonated at physiological pH, seems to be a crucial 254 
element in the activity of these compounds. This could mean that these compounds are 255 
disrupting the kinetoplast, which is, a well known lethal event for trypanosomes.31 256 
Compound 16 (carboxylic acid) trimer appeared to have an exceptionally high activity in 257 
terms of DNA binding. Also, the ionic group may be crucial in transport of the active 258 
compound to its target, and this is an important role in anti-trypanosomal compounds.32 It is 259 
obvious that all the elements in structure 16 are required because the dimer carboxylic acid 260 
24 is significantly active. The authors26 presented in their research a new class of heterocyclic 261 
oligoamide carboxylic acid exemplified by 16 as a new type of potential anti-trypanosomal 262 
compound. If this compound proved to be a DNA minor groove binder, this would mean that 263 
it has the same mode of action as the well-established anti-trypanosomal diamidines,32 which 264 
have been studied extensively. 265 
 266 
Scheme 5: Synthesis of heterocyclic oligoamide trimers 267 
 268 
  269 
 270 
 271 
Scheme 6:  Synthesis of C-isopropyl-substituted thiazole amide dimers 272 
  273 
At Strathclyde we have developed a large number of MGBs which are structurally similar to 274 
the natural product Distamycin.46 This compound was built from N-methylpyrrole amino acid 275 
amides and has an amidine end group (Scheme 1). Also, we modified a number of the 276 
fragments of the original structure. We have introduced less basic functional groups to 277 
replace the amidine at the C-terminus. Moreover, larger alkyl side chains have substituted the 278 
methyl groups in the pyrrole rings. And, thiazole rings have been introduced into the MGB. 279 
Also, aromatic rings have replaced the formyl group from Distamycin A and the N-terminal 280 
amide has been replaced by its isosteric alkene Fig. 5.9,16 281 
In summary the authors have demonstrated that their MGBs possess activity against T. b. 282 
brucei. Furthermore, five compounds have been identified as leads for further investigation, 283 
each with IC50 values lower than 40 nM. 284 
285 
 286 
Fig. 5: Exemplars of the types of MGBs investigated in reference [46] 287 
 288 
 289 
3. MGBs for the treatment of Tuberculosis 290 
Brucoli and co-workers33 evaluated several of these DNA-minor groove binding agents, 291 
Scheme 7 and Scheme 9. Tuberculosis is a well known disease and statistics show that 292 
around nine million people contracted it in 2013.34 To make matters worse, the occurrence of 293 
extensively-drug resistant TB (XDR-TB) strains requires prompt therapeutic intervention 294 
and, therefore, new molecules with novel mechanisms of action are urgently needed. 295 
Sequence-selective DNA minor groove-binding agents can be exploited to target specific 296 
promoter regions of M. tuberculosis DNA and disrupt transcription factors; this would cause 297 
bacterial cell death and overcome drug resistance-related issues. To examine this idea, 298 
Brucoli and co-workers33 synthesised and evaluated the anti-mycobacterial activity of a 299 
number of Distamycin A analogues, (Table 4) in which the constituent N-terminal pyrrole-300 
formamido moiety of distamycin was substituted with biaryl units. They have introduced the 301 
biaryl-motifs at the N-terminal position in order to improve the DNA sequence-selectivity of 302 
Distamycin, and overcome the H-bond recognition issues relative to polyamides containing 303 
several N-methylpyrrole rings, which are thought to be over-curved in comparison to the 304 
DNA helix.41 These compounds were prepared as illustrated in Scheme 7, Scheme 9 and 305 
Table 4. 306 
307 
 308 
Scheme 7: General synthetic scheme for the synthesis of the biaryl containing MGBs 309 
(a) HOBt, DIC, 16 h, rt; (b) Pd(PPh3)4, K2CO3, microwave (for more details see 310 
reference 33). 311 
  312 
 313 
 314 
Scheme 9: Schematic representation of the synthesis of the final compounds (for more 315 
examples see reference 33) 316 
  317 
Table 4: 318 
Representative examples of the Biological Activity Screening Results33 319 
Structure M. tuberculosis 
H37Rva
 
M. Bovis 
BCGa 
RAW 
264.7b 
SIc 
Distamycin 31.25 1.95 62.5 2 
 
62.5 125 62.5 1 
 
31.25 125 250 8 
 
250 125 62.5 0.25 
 
15.62 31.25 62.5 4 
 
62.5 7.8 62.5 1 
Isoniazid 0.05 0.05 3000 60,000 
Rifampin 0.05 0.05 700 14,000 
 320 
 321 
a MIC (µg/mL) 322 
b GIC50 (µg/mL) in RAW264.7 mouse macrophage cell line 323 
c SI = GIC50/MIC 324 
For more examples see reference (33). 325 
  326 
4. MGBs for the treatment of lung cancer 327 
We at the University of Strathclyde have also embarked upon the synthesis and evaluation of 328 
a range of minor groove binders designed for the treatment of lung cancer. There are a range 329 
of compounds prepared in our laboratories based on the principle that these compounds 330 
would inhibit the growth of lung cancer cells. Distamycin does not possess significant 331 
cytotoxicity; however, other classes of minor groove binders have shown significant 332 
possibility as anti-cancer agents, in particular those which are derived from the distamycin 333 
structure in Scheme 8.45 334 
 335 
Scheme 8: Representative exemplars of the structural variations in the MGB set 336 
investigated as potential candidates for treatment of lung cancer. 337 
 338 
5. Anti-malarial minor groove binders 339 
Recently Scott et al,51 published their research work in the field of combating malaria by 340 
using minor groove binders. There are worldwide efforts in the control and prevention of 341 
malaria. From 2000 to 2015 there was a dramatic reduction both in the incidence (37%) and 342 
mortality rate (60%) due to malaria infections; however, the threat of parasite resistance is 343 
still frightening and could undermine these achievements.52 Three of the five Plasmodium 344 
species which are known to infect humans (P. falciparum, P. Vivax and P. malariae) have all 345 
demonstrated resistance to commonly used antimalarial drugs. The resistance to Artemisinin 346 
monotherapy and also to the combination therapy (ACT) reported as a delayed clearance of 347 
infection with standard dosing regimens, there is a need for new antimalarial compounds. 348 
Those with alternative modes of action are of most value as cross-resistance generated to all 349 
compounds within the same chemical class or mode of action is a common phenomenon. In 350 
spite of how the work towards this goal is progressing, several heterocyclic compounds such 351 
as DDD107498, Fig.6, there is still the need to have a number of compounds in the pipeline 352 
as potential novel therapeutics should resistance emerge. A number of screening campaigns 353 
have identified new drug candidates which appear to be clustering to a small number of 354 
protein targets, for example PfATP4, PI4K and PfDHODH. The identification of new 355 
compounds with alternative targets or modes of action is an obvious route to take with the 356 
intention of minimizing the threat of cross resistance.53-57 357 
 358 
 359 
Fig. 6 Structure of DDD107498 360 
 361 
The data shown in (Table 5) illustrate the structures of both significantly active and inactive 362 
compounds. No significant activity was observed in compounds without an aromatic head 363 
group.42,43 The activity and selectivity were found almost entirely within the alkene-linked 364 
subset of compounds; the amidine-linked compounds were all at best weakly active and only 365 
one amide-linked compound had significant activity.58 Interestingly, this compound contains 366 
a C-alkylthiazole with an isopropyl chain, a structural feature that seems to promote 367 
antimalarial activity. Overall, five of the most active compounds, all alkene linked, contained 368 
a C-alkylthiazole (33-41). Even in the weakly active amidine series, the C-alkylthiazole 369 
noticeably increased the activity. Importantly, approximately equal activity was observed 370 
between the resistant and sensitive strains. 371 
  372 
Table 5: 373 
Representative examples of S-MGB Structures: Anti-malarial minor groove binders 374 
No Structure No Structure 
33 
 
34 
 
35 
 
36 
 
37 
 
38 
 
39 
 
40 
 
41 
 
  
 375 
 376 
1. Phase I clinical trial of our MGB 377 
Hundreds of MGBs were synthesised in our laboratory here at the University of Strathclyde. 378 
These were tested in a variety of ways for their biological activities. After several years of 379 
research, one of the MGBs was found to be very effective against Clostridium difficile (C. 380 
Diff). This drug candidate has been patented and licensed to a pharmaceutical company in 381 
Scotland. The synthesis of this drug, as can be seen in (Scheme 10) consists of two parts: 382 
head group which is stilbene like moiety and the second part of the molecule consists of two 383 
N-methyl pyrroles attached to an aminoethyl morpholine.16, 24(a), 43, 44 384 
 385 
 386 
 387 
 388 
Scheme 10: Schematic representation for the synthesis of MGB-BP-3 389 
 390 
MGB-BP-3 is an antibacterial drug which has a broad activity against a number of very 391 
important multi drug resistant Gram-positive pathogens. MGB Biopharma Ltd has managed 392 
to develop an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile 393 
infections which has passed Phase One clinical trials. There are many drugs are being used 394 
for the treatment of bacterial infections, however, these have been used for several decades 395 
and because of the rise in resistant strains of bacteria, therefore, the usefulness of many of 396 
these drugs is diminishing. MGB-BP-3 was first synthesised according to (Scheme 10) using 397 
a convergent method by which two parts of the molecule were prepared separately and then 398 
coupled at the last step. 399 
The crucial point of the MGB-BP3 class of antibacterial compounds is their selectivity for 400 
Gram-positive bacteria and they have no activity against mammalian cells. This became 401 
obvious from the data obtained from another compound AIK-20/25/1. This compound is 402 
almost as active as MGB-BP3. Fig. 7 shows the effect on cellular viability for this compound 403 
comparing a mammalian cell line (HS27 murine fibroblast) with Staphylococcus aureus. It 404 
can be seen from the Fig.8 that the difference is huge. There is no evidence of toxicity could 405 
be found with the HS27 cells but catastrophic death was found for the bacteria. The 406 
catastrophic bactericidal death is believed to be as a result of the minor groove binders 407 
interfering with a number of biochemical pathways that together lead to this catastrophic 408 
death.42 409 
  410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
Fig. 7: Selectivity for Gram-positive bacteria shown by AIK-20/25/1 (Courtesy of Chemistry 435 
& Biology Interface, reference 42) 436 
  437 
Effect of AIK-20/25/1 on HS27 Cells
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Conclusion: 438 
In this review article we have attempted to highlight the importance of antibiotic resistant 439 
bacteria and the crucial steps taken to tackle this issue which is affecting a vast number of 440 
people. The subject also deals with combating neglected third world diseases such as sleeping 441 
sickness. 442 
The natural product distamycin has been modified in so many ways. The tail group was 443 
changed by replacing the amidine moiety with a variety of tertiary amines; also, the methyl 444 
pyrrole(s) were replaced with a variety of either longer alkyl (branched alkyl) groups or with 445 
a different heterocyclic ring(s). The head group was replaced with a variety of heterocyclic, 446 
aromatic or stilbene-like moieties. 447 
The physical chemical behaviour as well as the molecular modelling of some of these DNA 448 
binding compounds was studied extensively. 449 
A variety of biological assays were performed in our laboratories and those of others, on a 450 
vast number of these DNA minor groove binder MGBs. Some of these results are tabulated in 451 
this review. 452 
One compound (MGB-BP3) which was initially synthesised in our laboratories and was 453 
subsequently developed further by a small pharmaceutical Scottish company (MGB 454 
Biopharma) was selected for the treatment of a gram positive bacteria Clostridium difficile 455 
(C. diff.) infections. This candidate drug has passed phase 1 clinical trial and has been 456 
approved for phase 2 clinical trials. 457 
 458 
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